Inside informationEnglish
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 08/10/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112042_20251008